Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | BDKRB2 | P30411 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887082 | 0.91 | PLG (0.50) | CPB2PLGSSTR3BDKRB2TACR1 | |
| SCHEMBL4879325 | 0.89 | CPB2 (0.50) | CPB2KDM1APLGEPHX1SSTR3 | |
| SCHEMBL4885602 | 0.89 | PLG (0.54) | CPB2KDM1APLGHPGDF12 | |
| SCHEMBL4884654 | 0.87 | NTMT1 (0.50) | CPB2PLGEPHX1BDKRB2TACR1 | |
| SCHEMBL4886971 | 0.83 | CHRNB2 (0.52) | PLGBDKRB2TACR1 | |
| SCHEMBL4887070 | 0.82 | PLG (0.55) | CPB2KDM1APLGHPGDKLKB1 | |
| SCHEMBL4885605 | 0.82 | KDM1A (0.47) | CPB2KDM1APLGSSTR3 | |
| SCHEMBL4888158 | 0.79 | BDKRB2 (0.51) | BDKRB2 | |
| SCHEMBL4879315 | 0.79 | CPB2 (0.50) | CPB2KDM1APLGSSTR3KLKB1 | |
| SCHEMBL4884646 | 0.77 | NTMT1 (0.51) | CPB2PLGEPHX1TACR1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | CPB2 1198/4885KDM1A 2425/4885PLG 3666/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | CPB2 1322/4885KDM1A 2543/4885PLG 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.